DEB-TACE+HAIC vs. HAIC for Large HCC

Unresectable Hepatocellular Carcinoma Clinical Trial

Official title:

Transarterial Chemoembolization With Drug-eluting Beads Plus Hepatic Arterial Infusion Chemotherapy Versus Hepatic Arterial Infusion Chemotherapy Alone for Large Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05263219
• Other study ID #: MIIR-09
• Status: Recruiting
• Phase: Phase 3
• Start date: February 10, 2022
• Est. completion date: February 9, 2026

Study information

• Verified date: June 2023
• Source: Second Affiliated Hospital of Guangzhou Medical University
• Contact: Mingyue Cai, Dr.
• Phone: +86-20-34156205
• Email: cai020[@]yeah.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large hepatocellular carcinoma (HCC).

Description:

This is a multicenter, prospective and randomized study to evaluate the efficacy and safety of DEB-TACE (with CalliSpheres) plus HAIC compared with HAIC alone for unresectable large HCC (>7cm).

230 patients with initially unresectable large HCC (> 7cm) will be enrolled in this study. The patients will receive either DEB-TACE plus HAIC (dTACE-HAIC) or HAIC as the primary treatment using an 1:1 randomization scheme. In the dTACE-HAIC arm, the microcatheter will be reserved at the proper/left/right hepatic artery and chemotherapy drugs (FOLFOX-based regimen) will be intra-arterially administered though the microcatheter. The treatment can be repeated on demand (at a 4-6-week interval usually) based on the evaluation of follow-up laboratory and imaging examination by the multidisciplinary team. In the HAIC arm, treatment will repeated once every 3 weeks for up to six cycles. During follow-up, the potential resectability of the tumor will be assessed by the multidisciplinary team (MDT). Once the tumors become resectable, curative surgical resection will be recommended for the patients.

The primary end point of this study is overall survival (OS). The secondary endpoints are tumor response (objective response rate and disease control rate), success rate of conversion to resection, progression-free survival (PFS), and adverse events (AEs).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 230
• Est. completion date: February 9, 2026
• Est. primary completion date: February 9, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with HCC confirmed by histology/cytology or diagnosed clinically.

• The maximum HCC lesion > 7 cm.

• Unresectable HCC evaluated by the surgeon team.

• At least one measurable intrahepatic target lesion.

• Patients without cirrhosis, or with cirrhosis but the liver function of Child-Pugh Class A.

• ECOG score of performance status = 1 point.

• Adequate organ and bone marrow function; the blood biochemical examination: platelet count =75×10^9/L, leukocyte >3.0×10^9/L, ASL and AST=5×ULN, creatinine=1.5×ULN, INR<1.5 or PT/APTT normal range.

• Life expectancy of at least 3 months.

Exclusion Criteria:

• Accompanied with tumor thrombus involving the main portal vein or bilateral first-order branch of portal vein.

• Accompanied with vena cava tumor thrombus.

• Extrahepatic metastasis.

• Previous treatment with TACE, HAIC, liver transplantation, resection, ablation, radiotherapy, or systemic therapy.

• Decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy.

• Those with organs (heart and kidneys) dysfunction who cannot tolerate TACE or HAIC treatment.

• History of other malignancies.

• Uncontrollable infection.

• History of HIV.

• Allergic to the drugs involved in the research.

• Patients with gastrointestinal bleeding within 30 days, or other bleeding> CTCAE grade 3.

• History of organ or cells transplantation.

• Those with bleeding tendency.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Unresectable Hepatocellular Carcinoma

Intervention

Procedure:
• dTACE-HAIC
For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered. During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination.
• HAIC
HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter. The treatment is repeated once every 3 weeks for up to six cycles.

Drug:
• dTACE-HAIC protocol
CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 µm are additionally injected. FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
• HAIC protocol
FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.

Locations

Country	Name	City	State
China	the Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong

Sponsors (8)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Guangzhou Medical University	Affiliated Hospital of Guangdong Medical University, First Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Hainan General Hospital, Jiangmen Central Hospital, Maoming People's Hospital, Zhongshan People's Hospital, Guangdong, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival (OS)	The time from date of randomization to death due to any cause.	4 years.
Secondary	Objective response rate (ORR) per mRECIST.	The proportion of patients with the best response of complete response (CR) or partial response (PR) according to mRECIST.	4 years.
Secondary	ORR per RECIST 1.1.	The proportion of patients with the best response of CR or PR according to RECIST 1.1.	4 years.
Secondary	Disease control rate (DCR) per mRECIST.	The proportion of patients with the best response of CR, PR, or stable disease (SD) according to mRECIST.	4 years.
Secondary	DCR per RECIST 1.1.	The proportion of patients with the best response of CR, PR, or SD according to RECIST 1.1.	4 years.
Secondary	Progression free survival (PFS) per mRECIST.	The time from date of randomization until the first occurrence of disease progression (according to mRECIST) or death due to any cause, whichever occurs first.	4 years.
Secondary	Progression free survival (PFS) per RECIST 1.1.	The time from date of randomization until the first occurrence of disease progression (according to RECIST 1.1) or death due to any cause, whichever occurs first.	4 years.
Secondary	Success rate of conversion to resection	The proportion of patients with initially unresectable large HCC who were evaluated by the surgical team as suitable for surgical resection after dTACE-HAIC or HAIC treatment.	4 years.
Secondary	Adverse Events (AEs)	Number of patients with AEs assessed by Common Terminology Criteria for Adverse Events v5.0.	4 years.